Biodexa Pharmaceuticals
Biodexa Pharmaceuticals
BDRX
NASDAQ
3.99
USD
-0.25%
About
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics.
The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery.
Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 131.2K |
| Three Month Average Volume | 31.4M |
| High Low | |
| Fifty-Two Week High | 8.81 USD |
| Fifty-Two Week Low | 0.55 USD |
| Fifty-Two Week High Date | 27 Nov 2023 |
| Fifty-Two Week Low Date | 30 Aug 2024 |
| Price and Volume | |
| Current Price | 0.55 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -16.97% |
| Thirteen Week Relative Price Change | -46.71% |
| Twenty-Six Week Relative Price Change | -63.22% |
| Fifty-Two Week Relative Price Change | -94.51% |
| Year-to-Date Relative Price Change | -82.67% |
| Price Change | |
| One Day Price Change | -0.54% |
| Thirteen Week Price Change | -42.97% |
| Twenty-Six Week Price Change | -59.56% |
| Five Day Price Change | -12.03% |
| Fifty-Two Week Price Change | -93.12% |
| Year-to-Date Price Change | -79.48% |
| Month-to-Date Price Change | -20.29% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.0647 USD |
| Book Value Per Share (Most Recent Quarter) | 2.0647 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.76665 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.76665 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -19.56491 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.63334 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.96395 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -11.7661 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -24.72403 USD |
| Normalized (Last Fiscal Year) | -11.77135 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -11.7661 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -24.72403 USD |
| Including Extraordinary Items (Last Fiscal Year) | -11.7661 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -24.72403 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.63539 USD |
| Cash Per Share (Most Recent Quarter) | 2.63539 USD |
| Cash Flow Per Share (Last Fiscal Year) | -11.29701 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -17.19425 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -17.93556 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,377 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,861 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,964.57% |
| Pretax Margin (Last Fiscal Year) | -1,964.57% |
| Pretax Margin (5 Year) | -2,111.10% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -2,103.41% |
| Operating Margin (Trailing Twelve Months) | -2,103.41% |
| Operating Margin (5 Year) | -2,179.51% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,858.01% |
| Net Profit Margin (Trailing Twelve Months) | -1,858.01% |
| Net Profit Margin (5 Year) | -1,926.06% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -94.62% |
| Tangible Book Value (5 Year) | -17.52% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -64.07% |
| Revenue Growth (3 Year) | -27.77% |
| Revenue Change (Trailing Twelve Months) | -45.49% |
| Revenue Per Share Growth | -93.45% |
| Revenue Growth (5 Year) | 3.56% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 1.51% |
| Total Debt (5 Year) | -18.01% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 98.80% |
| EPS Change (Trailing Twelve Months) | 99.91% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -7,228,460 |
| Net Debt (Last Fiscal Year) | -7,228,460 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 16 |
| Price to Sales (Trailing Twelve Months) | 16 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 6 |
| Long Term Debt to Equity (Most Recent Quarter) | 6 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -9,304,980 |
| Free Cash Flow (Trailing Twelve Months) | -9,304,980 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 10 |
| Total Debt to Equity (Most Recent Quarter) | 10 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -88.12% |
| Return on Assets (Trailing Twelve Months) | -88.12% |
| Return on Assets (5 Year) | -69.02% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -180.59% |
| Return on Equity (Trailing Twelve Months) | -180.59% |
| Return on Equity (5 Year) | -101.64% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -164.67% |
| Return on Investment (Trailing Twelve Months) | -164.67% |
| Return on Investment (5 Year) | -88.49% |